233 related articles for article (PubMed ID: 22986577)
21. 2'-Hydroxy-4-methylsulfonylchalcone enhances TRAIL-induced apoptosis in prostate cancer cells.
Ismail B; Fagnere C; Limami Y; Ghezali L; Pouget C; Fidanzi C; Ouk C; Gueye R; Beneytout JL; Duroux JL; Diab-Assaf M; Leger DY; Liagre B
Anticancer Drugs; 2015 Jan; 26(1):74-84. PubMed ID: 25192452
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
23. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
Yoo J; Park SS; Lee YJ
J Cell Biochem; 2008 Aug; 104(5):1636-46. PubMed ID: 18404675
[TBL] [Abstract][Full Text] [Related]
24. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
25. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
26. A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.
Bemis DL; Capodice JL; Desai M; Buttyan R; Katz AE
Clin Cancer Res; 2004 Aug; 10(15):5282-92. PubMed ID: 15297432
[TBL] [Abstract][Full Text] [Related]
27. Sanguinarine sensitizes human gastric adenocarcinoma AGS cells to TRAIL-mediated apoptosis via down-regulation of AKT and activation of caspase-3.
Choi WY; Jin CY; Han MH; Kim GY; Kim ND; Lee WH; Kim SK; Choi YH
Anticancer Res; 2009 Nov; 29(11):4457-65. PubMed ID: 20032392
[TBL] [Abstract][Full Text] [Related]
28. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
[TBL] [Abstract][Full Text] [Related]
29. PI3 Kinase inhibition on TRAIL-induced apoptosis correlates with androgen-sensitivity and p21 expression in prostate cancer cells.
Kadowaki Y; Chari NS; Teo AE; Hashi A; Spurgers KB; McDonnell TJ
Apoptosis; 2011 Jun; 16(6):627-35. PubMed ID: 21437722
[TBL] [Abstract][Full Text] [Related]
30. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation.
Kim YH; Lee YJ
J Cell Biochem; 2007 Mar; 100(4):998-1009. PubMed ID: 17031854
[TBL] [Abstract][Full Text] [Related]
31. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
33. Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Yoo J; Lee YJ
Mol Pharmacol; 2007 Dec; 72(6):1586-92. PubMed ID: 17848598
[TBL] [Abstract][Full Text] [Related]
34. Tumor suppressor XIAP-Associated factor 1 (XAF1) cooperates with tumor necrosis factor-related apoptosis-inducing ligand to suppress colon cancer growth and trigger tumor regression.
Tu SP; Sun YW; Cui JT; Zou B; Lin MC; Gu Q; Jiang SH; Kung HF; Korneluk RG; Wong BC
Cancer; 2010 Mar; 116(5):1252-63. PubMed ID: 20082449
[TBL] [Abstract][Full Text] [Related]
35. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
Lakshmikanthan V; Kaddour-Djebbar I; Lewis RW; Kumar MV
Int J Cancer; 2006 Jul; 119(1):221-8. PubMed ID: 16450389
[TBL] [Abstract][Full Text] [Related]
36. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
37. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
Shankar S; Ganapathy S; Srivastava RK
Clin Cancer Res; 2008 Nov; 14(21):6855-66. PubMed ID: 18980980
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand.
Fang F; Wang AP; Yang SF
Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761
[TBL] [Abstract][Full Text] [Related]
39. Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells.
Shimada O; Wu X; Jin X; Nouh MA; Fiscella M; Albert V; Matsuda T; Kakehi Y
Urology; 2007 Feb; 69(2):395-401. PubMed ID: 17320696
[TBL] [Abstract][Full Text] [Related]
40. Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Festuccia C; Gravina GL; D'Alessandro AM; Muzi P; Millimaggi D; Dolo V; Ricevuto E; Vicentini C; Bologna M
Endocr Relat Cancer; 2009 Jun; 16(2):401-13. PubMed ID: 19153211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
